相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2020)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer
Kazuo Kobayashi et al.
ONCOLOGY (2019)
Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
Teiji Kuzuya et al.
HEPATOLOGY RESEARCH (2019)
Regorafenib in Patients with Antiangiogenic-Naive and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial
Rachel P. Riechelmann et al.
ONCOLOGIST (2019)
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
Changhoon Yoo et al.
INVESTIGATIONAL NEW DRUGS (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting
Kensei Yamaguchi et al.
ONCOLOGIST (2019)
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
Atsushi Hiraoka et al.
CANCER MEDICINE (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Jordi Bruix et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
Michael Gerisch et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
Joon Oh Park et al.
ONCOTARGET (2016)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
Joo Ho Lee et al.
CANCER (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients
Atsunari Kawashima et al.
EUROPEAN JOURNAL OF CANCER (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)
DW Blayney et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
